Summit Therapeutics Inc.
ivonescimab
first-line metastatic NSCLC, squamous tumors
Resolved
38days ago
Phase 2 readout · May 30, 2026
What's at stake
Phase 2 trial results for ivonescimab in first-line metastatic NSCLC, squamous tumors are due May 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“Summit Therapeutics Inc. (NASDAQ: SMMT) today presented new results from the AK112-206 trial (NCT05382442), a global, open-label, multicenter Phase II study in �rst-line metastatic colorectal cancer (mCRC) co-sponsored by Summit and Akeso, ”